Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Meyer J, Silas P, Ouedraogo G.L, McElwee K, Keep G, Trammel J, Peng Y, Scully IL, PhD, 5 William C. Gruber WC, Scott DA, Watson W May 12, 2023 ESPID 2023 Pneumococcal Disease

A Phase 3 Trial Evaluating the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age

View Presentation
Poster
Hajdu G, Huges T, Ouedraogo G.L., Flint L, Young M, Parikh V, Lee D-Y, Peng Y, Gruber WC, Scott DA, Watson W May 12, 2023 ESPID 2023 Pneumococcal Disease

A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants

View Presentation
Poster
Di Virgilio R, Pagliaro A, Iantomasi R, Wilson M, McDade C, Colombo GL, Amodio E, Montuori EA, Warren S, Perdrizet J May 12, 2023 ESPID 2023 Pneumococcal Disease

Cost-effectiveness of a 20-Valent Paediatric Pneumococcal Conjugate Vaccine Compared With a 15-Valent Pneumococcal Conjugate Vaccine in Italy

View Presentation
Poster
Dorange A-C, Palmborg A, Michele M, Warren S, Perdrizet J. May 12, 2023 ESPID 2023 Pneumococcal Disease

Cost-effectiveness of the 20-valent Pneumococcal Vaccine Compared With the 15-valent Pneumococcal Vaccine in Swedish Children

View Presentation
Poster
Lin T-Y, Chiu CH, . Woo P C.Y., Muttalif AR, Dhar R, Kit LC, Morales G, Ozbilgili E May 12, 2023 ESPID 2023 Pneumococcal Disease

Distribution and Antibiotic Resistance in Children in Asia, 2012–2022

View Presentation
Poster
Averin A, Pelton SI, Weycker D, Huang L, Jeffrey Vietri J, Tort MJ, Arguedas Mohs AG, Alejandro Cane A, Lapidot R. May 12, 2023 ESPID 2023 Pneumococcal Disease

Early-Life Pneumonia Identifies Children at Elevated Risk of Chronic Respiratory Diseaseesp

View Presentation
Poster
Kossyvaki V, Barmpouni M, Wilson M, Warren S, Perdrizet J May 12, 2023 ESPID 2023 Pneumococcal Disease

Estimating the Clinical and Economic Impact of Switching from PCV13 to Higher-Valent Alternatives (PCV15 and PCV20) for Children in Greece

View Presentation
Poster
Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, Ellsbury G, Perdrizet J. May 12, 2023 ESPID 2023 Pneumococcal Disease

Estimating the Cost-effectiveness of Switching to Higher-Valent Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

View Presentation
Oral Presentation
Yang, J May 12, 2023 ESPID 2023 Coronovirus Disease

Healthcare resource utilisation (HCRU) and costs associated with acute COVID-19 in paediatric patients managed in the community or hospital setting in England: a population-based study

View Presentation
Poster
Jones JC, Tipton M, Zolotas L, Jason D. Maguire J.D., Belanger K, Moughan B, Liu Y, Maansson R, O'Neill R, Balmer P, Peyrani P, Beeslaar J. May 12, 2023 ESPID 2023 Meningococcal Disease

Pentavalent MenABCWY Meningococcal Vaccine Administered on a 0-12-Month Schedule is safe and Well-Tolerated and Provides A High Degree of Protective Immunosity in Healthy Adolescents

View Presentation